0
No hay productos en el carro de la compra
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Casa > Metabolic Disease Drug Development Tools

Metabolic Disease Drug Development Tools

Metabolic disorders (MDs) are a group of complex diseases caused by defects in enzymes or proteins within metabolic pathways, typically resulting from genetic factors, environmental influences, or a combination of both. These disorders often involve abnormalities in carbohydrate metabolism, lipid metabolism, amino acid metabolism, mineral, and bone metabolism, ultimately disrupting normal physiological functions in the body.

ACROBiosystems remains dedicated to providing biopharmaceutical users with comprehensive drug development tools. To meet the needs of metabolic disorder drug development, ACROBiosystems has developed high-quality recombinant proteins, functional cells, antibodies, magnetic beads and inhibitor screening kits targeting key disease-related targets. These products are designed to support various stages of drug development, fully addressing your biologics development needs!

Glucose Metabolism Disorders

The Development of Diabetes

The Development of Diabetes[1]

Glucose Metabolism Disorders are a group of conditions that affect the body's ability to process glucose and other sugars, primarily including Type 1 Diabetes (T1D) and Type 2 Diabetes (T2D). Type 1 Diabetes results from insufficient insulin secretion, while Type 2 Diabetes is characterized by insulin resistance and relative insulin deficiency.
Glycemic disorders Proteins
  • Type 1 Diabetes

  • Type 2 Diabetes

  • INSR

  • GLP1R

  • GIPR

  • GCGR

  • DPP4

  • TNF-α

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • INSR

  • GLP1R

  • GIPR

  • GCGR

  • DPP4

  • PCSK9

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description

Lipid Metabolism Disorders

Lipid Metabolism Process

Lipid Metabolism Process[2]

Lipid metabolism disorders are a group of conditions caused by abnormalities in the metabolism of lipids, such as cholesterol and triglycerides. Common disorders include hyperlipidemia, hypercholesterolemia, atherosclerosis, and non-alcoholic fatty liver disease. These conditions are closely linked to imbalances in the synthesis, breakdown, transport, and storage of lipids in the body. Dysregulated lipid metabolism can result in abnormal elevations or reductions in blood lipid levels, which can, in turn, affect cardiovascular health, liver function, and overall metabolic balance.
Lipid Metabolism Disorders Proteins
  • Hypercholesterolemia

  • Obesity

  • Atherosclerosis

  • Non-Alcoholic Steatohepatitis (NASH)

  • PCSK9

  • ANGPTL3

  • ASGR1

  • THRA

  • THRB

  • LDLR

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • GLP1R

  • GIPR

  • GCGR

  • FGF21

  • Act R

  • GDF15

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • INSR

  • PCSK9

  • IL1B

  • GLP1R

  • IFNAR1

  • APOA1

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • GLP1R

  • FGF19

  • FGF21

  • THRA

  • THRB

  • TNF-α

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description

Amino Acid Metabolism Disorders

Amino Acid Metabolism Process

Amino Acid Metabolism Process[3]

Amino acid metabolism disorders are a group of inherited genetic diseases caused by abnormalities in specific amino acid metabolic pathways. These disorders are typically due to enzyme deficiencies or dysfunctions in transport proteins, leading to the abnormal accumulation or deficiency of amino acids and their metabolic products, which in turn cause various clinical symptoms. Common types include phenylketonuria (PKU), maple syrup urine disease (MSUD), homocystinuria, and isovaleric acidemia.
Amino Acid Metabolism Disorders Proteins
  • Inherited Amino Acid Metabolism Defects

  • DDC

  • TGF-β

  • Complement C5

  • ARG1

  • ETAR

  • ETBR

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description

Mineral and bone metabolism disorders

Calcium-Phosphate Metabolism and Related Hormonal Regulation

Calcium-Phosphate Metabolism and Related Hormonal Regulation[4]

Mineral and bone metabolism disorders refer to a group of diseases caused by abnormalities in the metabolism of minerals (such as calcium, phosphorus, magnesium, etc.) or imbalances in bone metabolism. These disorders include osteoporosis, osteomalacia, rickets, and thyroid dysfunction. They are typically associated with disruptions in the absorption, utilization, storage, and excretion of minerals, which in turn affect the normal formation, remodeling, and mineralization of bone tissue.
Mineral and Bone Metabolism-Related Indications Proteins
  • Osteoporosis

  • Hyperthyroidism

  • Hypothyroidism

  • PTHR

  • RANKL

  • IFNGR

  • SOST

  • Integrin a4b7

  • Siglec-15

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • TSHR

  • TPO

  • IGF1R

  • FCGRT

  • IL17A

  • IL6RA

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description
  • THRA

  • THRB

Disease-related TargetProduct TypesCat. No.Product Description
Disease-related TargetProduct TypesCat. No.Product Description

References

  • 1. Haythorne, E., Rohm, M., van de Bunt, M. et al. Diabetes causes marked inhibition of mitochondrial metabolism in pancreatic β-cells. Nat Commun 10, 2474 (2019). https://doi.org/10.1038/s41467-019-10189-x

  • 2. Badimon, Lina & Chiva-Blanch, Gemma. (2019). Lipid Metabolism in Dyslipidemia and Familial Hypercholesterolemia. 10.1016/B978-0-12-811297-7.00024-X.

  • 3. Wang Z, Wu X, Chen HN, Wang K. Amino acid metabolic reprogramming in tumor metastatic colonization. Front Oncol. 2023 Mar 14;13:1123192. doi: 10.3389/fonc.2023.1123192. PMID: 36998464; PMCID: PMC10043324.

  • 4. Montaner Ramón A. Risk factors of bone mineral metabolic disorders. Semin Fetal Neonatal Med. 2020 Feb;25(1):101068. doi: 10.1016/j.siny.2019.101068. Epub 2019 Dec 2. PMID: 31862224.

ACRO Quality

This web search service is supported by Google Inc.

totop
Email
Correo electrónico
Fax
Fax
+1 888-377-6111
Address
Address
Lichtstrasse 35,4056 Basel, Switzerland

Dejar un mensaje